FULC
NASDAQFulcrum Therapeutics Inc.
Price$7.84-0.08 (-0.95%)
01:30 PM07:45 PM
News · 26 weeks44-50%
2025-11-022026-04-26
Mix1990d
- Insider6(32%)
- Other6(32%)
- Earnings3(16%)
- SEC Filings3(16%)
- Offering1(5%)
Latest news
25 items- PRFulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ETCAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2026 financial results will be released on Monday, April 27, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
- PRMedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell DiseaseCAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people affected by sickle cell disease and their caregivers, and Fulcrum Therapeutics Inc. (Fulcrum) (NASDAQ:FULC), a leader in advancing therapies for underserved patient populations, today announced a new partnership designed to help streamline and expedite emergency department (ED) care for people living with sickle cell disease (SCD) through rapid access to patient-specific care plans. Individuals living with SCD, an inherited blood disorder,
- PRFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employee 34,000 options to pur
- PRFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m. ET. The webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics' webs
- SECSEC Form S-8 filed by Fulcrum Therapeutics Inc.S-8 - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- SECSEC Form 10-K filed by Fulcrum Therapeutics Inc.10-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- SECFulcrum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- PRFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities; cash runway into 2029 ― CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therap
- PRFulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) reported zero VOCs during the treatment period ― ― Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ― ― Fulcrum plans to initiate a pote
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)
- PRFulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell DiseaseCAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine. To register for
- PRFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employee 70,000 options to purc
- INSIDERAmendment: Director Gould Robert J sold $163,089 worth of shares (15,000 units at $10.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)4/A - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Musso Alan A4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERSEC Form 4 filed by Principal Accounting Officer Tourangeau Greg4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Oltmans Curtis Gale4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERDirector Gould Robert J sold $160,857 worth of shares (15,000 units at $10.72), decreasing direct ownership by 3% to 454,864 units (SEC Form 4)4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERSEC Form 4 filed by Officer Sapir Alex4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- SECFulcrum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)
- ANALYSTAnalyst initiated coverage on Fulcrum Therapeutics with a new price targetAnalyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00
- PRFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employees 30,400 options to
- PRFulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulc
- INSIDERDirector Gould Robert J sold $178,089 worth of shares (15,000 units at $11.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
- INSIDERChief Legal Officer Oltmans Curtis Gale sold $44,600 worth of shares (3,452 units at $12.92), decreasing direct ownership by 25% to 10,252 units (SEC Form 4)4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)